| Sep 25 |
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
|
| Aug 29 |
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
|
| Aug 11 |
2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript
|
| Aug 10 |
2seventy bio, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
|
| Aug 7 |
2seventy bio GAAP EPS of $0.45, revenue of $8.96M
|
| Aug 7 |
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
|
| Aug 5 |
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
|
| Jul 9 |
2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition
|
| Jul 4 |
Broker Revenue Forecasts For 2seventy bio, Inc. (NASDAQ:TSVT) Are Surging Higher
|
| Jun 27 |
Novo Nordisk buys 2seventy bio’s Hemophilia A program
|
